Dabigatran etexilate for prevention of venous thromboembolism

References
1 US Department of Health and Human Services.. The surgeon general’s call to action to prevent deep vein thrombosis and pulmonary embolism 2008. Available at: http://www.surgeongeneral.gov/topicsdeepvein/calltoaction/call-to-action-on-dvt-2008.pdf.
2 The House of Commons Health Committee Report on the Prevention of Venous Thromboembolism in Hospitalised Patients – Second Report of Session 2004–05. The Stationery Office 2005. Available at: http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/99/99.pdf.
3 Cohen AT, Agnelli G, Anderson FA. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
4 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (06) 381S-453S.
5 Caprini JA. Anticoagulants for thrombosis prophylaxis following surgery: a continuing saga. Thromb Haemost 2008; 99: 993-994.
6 Borris LC. Barriers to the optimal use of anticoagulants after orthopaedic surgery. Arch Orthop Trauma Surg. 2008 in press.
7 Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008; 28: 380-386.
8 Wolowacz SE, Roskell NS, Plumb JM. et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty: A meta-analysis. Thromb Haemost 2009; 101: nn.
9 Eriksson BI, Dahl OE, Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
10 Eriksson BI, Dahl OE, Rosencher N. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 05: 2178-2185.
11 The RE-MOBILIZE Writing Committee.. The oral thrombin inhibitor dabigatran etexilate vs. the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2008 in press.
12 Kakkar AK, Brenner B, Dahl OE. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty. Lancet 2007; 372: 31-29.
13 Eriksson BI, Borris LC, Friedman RJ. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
14 Lassen MR, Ageno W, Borris LC. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
15 Eikelboom JW, Weitz JI. Selective factor Xa inhibition for thromboprophylaxis. Lancet 2008; 372: 6-8.
16 Ezekowitz MD, Reilly PA, Nehmiz G. et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 1419-1426.